Literature DB >> 30306208

MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.

Anahita Nosrati1, Ahmad Monabati2, Alireza Sadeghipour3, Fatemeh Radmanesh4, Akbar Safaei5, Sajjadeh Movahedinia6,7.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare specific subtype of non-Hodgkin lymphoma limited to the brain, leptomeninges, spinal cord, or eyes without any systemic presentation and relapse which mostly takes place in CNS. In more than 95% of patients, it is of diffuse large B cell lymphoma (DLBCL) type. Categorizing PCNSL to germinal center cell like or activated B cell like, as we usually do for DLBCL NOS, may not be applicable for predicting outcome. Possible prognostic significance of MYC, BCL2, and/or BCL6 rearrangements may be important given what we know about their impact in systemic DLBCL, but we have limited knowledge about the status of double or triple hit molecular changes in PCNSL. Here, we have investigated prevalence of these molecular alterations in PCNSL. Two independent tissue microarrays constructed from 78 formalin-fixed paraffin-embedded blocks of confirmed PCNSL were tested for rearrangement of MYC, BCL2, and BCL6 by interphase fluorescent in situ hybridization (FISH) using break apart dual color probes. BCL6 translocation was detected in 15 (12%) cases. Translocation involving MYC and BCL2 was identified in 3 cases (3.8%) and 1 case (1.3%) respectively. One double hit lymphoma was discovered with both MYC/BCL2 translocation (1.3%). To the best of our knowledge, few organized studies have been conducted for MYC, BCL2, and/or BCL6 rearrangement in PCNSL. This study is evaluating large number of PCNSL. Double or triple hit events which are rarely seen in PCNSL.

Entities:  

Keywords:  BCL2; BCL6; MYC; Primary central nervous system lymphoma; Rearrangement

Mesh:

Substances:

Year:  2018        PMID: 30306208     DOI: 10.1007/s00277-018-3498-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

1.  Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.

Authors:  Diego Villa; King L Tan; Christian Steidl; Susana Ben-Neriah; Muntadhar Al Moosawi; Tamara N Shenkier; Joseph M Connors; Laurie H Sehn; Kerry J Savage; David W Scott; Randy D Gascoyne; Graham W Slack
Journal:  Blood Adv       Date:  2019-12-10

Review 2.  Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?

Authors:  K Grace Ho; Christian Grommes
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

3.  The genomic and transcriptional landscape of primary central nervous system lymphoma.

Authors:  Josefine Radke; Naveed Ishaque; Randi Koll; Zuguang Gu; Elisa Schumann; Lina Sieverling; Sebastian Uhrig; Daniel Hübschmann; Umut H Toprak; Cristina López; Xavier Pastor Hostench; Simone Borgoni; Dilafruz Juraeva; Fabienne Pritsch; Nagarajan Paramasivam; Gnana Prakash Balasubramanian; Matthias Schlesner; Shashwat Sahay; Marc Weniger; Debora Pehl; Helena Radbruch; Anja Osterloh; Agnieszka Korfel; Martin Misch; Julia Onken; Katharina Faust; Peter Vajkoczy; Dag Moskopp; Yawen Wang; Andreas Jödicke; Lorenz Trümper; Ioannis Anagnostopoulos; Dido Lenze; Ralf Küppers; Michael Hummel; Clemens A Schmitt; Otmar D Wiestler; Stephan Wolf; Andreas Unterberg; Roland Eils; Christel Herold-Mende; Benedikt Brors; Reiner Siebert; Stefan Wiemann; Frank L Heppner
Journal:  Nat Commun       Date:  2022-05-10       Impact factor: 17.694

4.  Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.

Authors:  Qiaojuan Zhu; Yazhao Li; Yang Guo; Linjun Hu; Zunqiang Xiao; Xin Liu; Jiahui Wang; Qiuran Xu; Xiangmin Tong
Journal:  J Cell Mol Med       Date:  2019-09-04       Impact factor: 5.310

5.  Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.

Authors:  Prakash Ambady; Nancy D Doolittle; Christopher P Fox
Journal:  Ann Lymphoma       Date:  2021-09

6.  Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.

Authors:  Bishan Dass Radotra; Mayur Parkhi; Debajyoti Chatterjee; Budhi Singh Yadav; Nagarjun Rao Ballari; Gaurav Prakash; Sunil Kumar Gupta
Journal:  Surg Neurol Int       Date:  2020-12-11

7.  Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.

Authors:  Jinuk Kim; Tae Gyu Kim; Hyoun Wook Lee; Seok Hyun Kim; Ji Eun Park; Moonok Lee; Young Zoon Kim
Journal:  Curr Oncol       Date:  2021-11-12       Impact factor: 3.677

8.  miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN.

Authors:  Weihao Wu; Longtian Chen; Congjie Chen; Lian Yu; Junqiong Zheng
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.